Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest CSL Behring Stories

2012-02-15 07:30:00

INTERLAKEN, Switzerland, Feb. 15, 2012 /PRNewswire/ -- CSL Behring announced today the four recipients of the 2012 Interlaken Leadership Awards. Now in its second year, the Interlaken Leadership Awards program recognizes scientists whose proposals are likely to advance innovative medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders. The total value of the four awards is estimated to be more than $1 million USD....

2012-02-02 08:45:00

ST. GALLEN, Switzerland, Feb. 2, 2012 /PRNewswire/ -- CSL Behring today announced the results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B. Results of the study, which were presented during an oral session at the Gesellscaft fur Thrombose- und Hameostasegorschung (GTH) congress in Switzerland, showed that rIX-FP was well tolerated in all patients and lasted longer in the...

2012-01-12 08:15:00

VIENNA, Jan. 12, 2012 /PRNewswire/ -- CSL Behring has announced that the first site has been initiated in its global phase II/III, multi-center study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The site is located in Vienna, Austria. The prospective, open-label study will enroll adolescents and adults (12 - 65 years) who have hemophilia B. CSL Behring, in collaboration with...

2012-01-03 09:32:00

KING OF PRUSSIA, Pa., Jan. 3, 2012 /PRNewswire/ -- CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert(®), C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder. With appropriate training from a physician, patients can now self-administer...

2011-12-02 07:00:00

KING OF PRUSSIA, Pa., Dec. 2, 2011 /PRNewswire/ -- CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations that help people who use plasma-derived or recombinant therapies to manage rare and serious medical disorders. CSL Behring has awarded more than $600,000 in grants to...

2011-11-05 07:00:00

BOSTON, Nov. 5, 2011 /PRNewswire/ -- New findings demonstrate that treatment with C1-esterase inhibitor (C1-INH) concentrate is effective in treating acute swelling attacks in children and adolescents with type I or type II hereditary angioedema (HAE), a rare and serious genetic disorder. Study results show that the outcomes of treatment with C1-INH during acute HAE attacks in children and adolescents are comparable to the outcomes observed in adults. Results of the analysis will be...

2011-10-20 07:00:00

KING OF PRUSSIA, Pa., Oct. 20, 2011 /PRNewswire/ -- CSL Behring announces publication of its Key Issues Dialogue on "Access to Care" which addresses many of the practices that impede access to care for people with rare and serious medical disorders, and possible solutions. This discussion is especially relevant now as healthcare reform is being implemented to assure that people with rare diseases do not end up with reduced care as an unintended consequence. (Logo:...

2011-10-06 15:45:00

KING OF PRUSSIA, Pa., Oct. 6, 2011 /PRNewswire/ -- CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies that does business in 27 countries, has been named Life Sciences Company of the Year by Philadelphia Business Journal and Pennsylvania Bio. The King of Prussia-based business is a subsidiary of CSL Limited (ASX:CSL). (Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO ) The award honors a life sciences company in the Greater...

2011-10-03 07:00:00

"Raise Your Voice!" teaches them to be their own best advocate, particularly in tough budget times when legislation and policy decisions could affect their access to care. KING OF PRUSSIA, Pa., Oct. 3, 2011 /PRNewswire-USNewswire/ -- Young people between the ages of 15 and 22 converged on Washington, D.C. this summer, eager to tell elected officials their personal stories. The stories are as varied as the towns and cities from where they hail, places like San Antonio, Pittsburgh, Des...

2011-09-01 12:00:00

ANNAPOLIS, Md., Sept. 1, 2011 /PRNewswire/ -- This month, Californians are recognizing "Plasma Protein Therapies Month," by raising awareness for the valuable contributions of plasma donors throughout the "Golden State" and for the rare, genetic diseases treated with the therapies that are made possible through plasma donation. Plasma protein therapies, which include plasma-derived therapies and recombinant blood clotting factors (a biotechnology product), are used every day to treat...